Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AEterna Zentaris, Sanofi-Aventis Sign BPH Drug Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

AEterna Zentaris, Sanofi-Aventis Sign BPH Drug Pact

AEterna Zentaris Inc. signed a development, commercialization and licensing agreement with Sanofi-Aventis for cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AEterna Zentaris signed a development, commercialization and licensing agreement with Sanofi-Aventis for cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, is currently in Phase III development for BPH, a non-cancerous enlargement of the prostate.

Under the terms of the agreement, AEterna Zentaris will receive an initial $30 million in upfront payments and is eligible to receive as much as $135 million in additional payments based on certain regulatory and commercial milestones, as well as royalties on future sales in the U.S. Sanofi-Aventis will be responsible for the commercialization and booking of sales in the U.S., however, AEterna Zentaris has retained certain rights to co-promote cetrorelix for BPH in the U.S. Sanofi-Aventis may perform future Phase IIIb and Phase IV trials, while AEterna Zentaris will have free access to all data for other territories.

“We are delighted to have a partner such as Sanofi-Aventis who has a proven track record in urology. This partnership marks an important milestone in our quest to bring cetrorelix to market, which could provide millions of men with a novel treatment for BPH. Furthermore, this compound could generate significant long-term revenue for the company while building value for our shareholders,” said Juergen Engel, Ph.D., president and chief executive officer of AEterna Zentaris.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters